Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

🏆 Top 10📊 OpenAlex

#2PRI RANKED

Most Cited Paper

in Retinal Development and Disorders

18 Months Post-Publication

Class of 2026

“Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study”

AuthorsPeter A Campochiaro et al.

Peter A. Campochiaro

JournalThe Lancet

Johns Hopkins University School of Medicine

Citations58

DOI10.1016/s0140-6736(24)00310-6

A research intelligence initiative by Pepkio

pri.pepkio.com

Topics

RGX-314 · gene therapy · neovascular AMD · Subretinal injection · Phase 1/2 clinical trial · dose escalation · Anti-VEGF therapy · AAV8 vector · Subretinal injection · choroidal neovascularization · neovascular AMD · intravitreal injection frequency reduction · sustained transgene expression · retinal gene transfer

Share on X

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Development and Disorders Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-development-and-disorders/2026. Accessed 2026-10-24.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459